Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610437 | 1.00 | CYP11B1 (0.56) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL30610425 | 0.86 | CYP11B1 (0.74) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL28352286 | 0.86 | CYP11B1 (0.74) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL225893 | 0.85 | CYP11B2 (0.78) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21803770 | 0.80 | CYP11B1 (0.55) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL30416680 | 0.79 | CYP11B1 (0.53) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15770240 | 0.78 | CYP2D6 (0.46) | CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL29477093 | 0.78 | CYP2D6 (0.46) | CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL5917995 | 0.78 | KDM4E (0.55) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL15784018 | 0.78 | RPS6KA3 (0.57) | RPS6KA3MAPTSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110719910-B | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | disclosed |
| CN-110719910-A | Novel inhibitors | 前体生物药物股份公司 | 2020-01-21 | — | — | CN | disclosed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | CYP11B1 391/4885CYP11B2 421/4885CYP1A2 839/4885 |
| US-20200377493-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | CYP11B1 1926/4885CYP11B2 1504/4885CYP1A2 723/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | CYP11B1 1607/4885CYP11B2 1264/4885CYP1A2 714/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | CYP11B1 1464/4885CYP11B2 1049/4885CYP1A2 744/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | CYP11B1 1611/4885CYP11B2 1565/4885CYP1A2 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.